Vaccine developed by Thai startup to be tested on humans in September | Inquirer News
Close  

Vaccine developed by Thai startup to be tested on humans in September

/ 05:54 PM July 19, 2021
thai vaccine

The Nation/Asia News Network

BANGKOK — The Thai government has said that a potential vaccine derived from plant protein, or subunit vaccine, which uses the same technology as Novavax, could be ready for production in a few weeks.

Deputy government spokesperson Ratchada Thanadirek said the factory was ready to produce the vaccine.

ADVERTISEMENT

The vaccine has been developed by Baiya Phytopharm Co Ltd, a Thai startup company.

A subunit vaccine presents one or more antigens to the immune system without introducing pathogen particles, whole or otherwise.

FEATURED STORIES

The research team will send the factory form to the Food and Drug Administration to inspect the factory.

The vaccine is expected to begin production in the next few weeks and will undergo early human testing around September 2021 as planned.

The team will officially seek in August about 100 volunteers who are in good health, aged between 18-55 years and 65-75 years.

Once the vaccine passes the process successfully, it is expected that it can be produced for Thai people to use in the middle of 2022. People will receive two vaccinations, three weeks apart, and it will sell at around THB300-500 per dose.

RELATED STORY

COVID-19 vaccines developed by Thai researchers undergoing human trials

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19 Vaccines, Health, Thailand
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.